STOCKHOLM, Sweden, Nov. 2, 2005 (PRIMEZONE) -- Active Biotech:
-- Laquinimod safe at higher dose for MS patients
-- Longer survival rate for renal cancer patients treated with
first-generation ANYARA
-- Confirmed ANYARA tumor localization in cancer patients
-- Expanded TASQ clinical studies for prostate cancer patients
-- SLE 57-57 project; ready to initiate patient studies
-- Acquisition of research facility in Lund
-- Net sales: SEK 6.5 M (68.2)
-- Operating loss: SEK 92.2 M (loss: 126.6)
-- Loss after tax: SEK 91.9 M (loss: 109.5)
-- Loss per share for the period: SEK 2.58 (loss: 3.16)
To view the full press release: http://hugin.info/1002/R/1019179/160218.pdf